OncoMatch/Clinical Trials/NCT06478693
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
Is NCT06478693 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including MT-303 and MT-303 +Atezolizumab + Bevacizumab for hepatocellular carcinoma.
Treatment: MT-303 · MT-303 +Atezolizumab + Bevacizumab — This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: GPC3 expression
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Liver function
child-pugh score: class a
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06478693 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require GPC3?
Yes, GPC3 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages